Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma

For developing generic, soft-gelatin capsule formulations of pharma products

Glenmark Pharmaceuticals has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L., granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products.

Under this agreement, Glenmark receives exclusive rights to the United States and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales. In addition, the agreement provides for the companies to add further soft-gelatin product candidates for development and commercialization, as new branded, softgelatin, capsule-based drug products become available in the marketplace.

 

Powered by Capital Market - Live News